Position in ACET
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$2,370,600
+$502,107 QoQ
Shares Held
274,375
0.0% QoQ
Ownership
2.93%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#6
of 56 holders
Holding Since
Mar 2021
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ACET Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ADAGE CAPITAL PARTNERS GP, L.L.C. holds $4,238,954,223 across 126 Biotechnology names. ACET ranks #108 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ROIV |
Roivant Sciences Ltd.
|
10,349,328 | $366,262,717 | |
| 2 | PRAX |
Praxis Precision Medicines, Inc.
|
1,015,480 | $339,972,549 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
393,964 | $195,693,737 | |
| 4 | TNGX |
Tango Therapeutics, Inc.
|
5,600,000 | $175,056,000 | |
| 5 | BBIO |
BridgeBio Pharma, Inc.
|
2,252,000 | $167,728,960 | |
| 6 | SYRE |
Spyre Therapeutics, Inc.
|
1,722,300 | $152,905,794 | |
| 7 | TVTX |
Travere Therapeutics, Inc.
|
2,569,356 | $145,965,114 | |
| 8 | RPRX |
Royalty Pharma plc
|
2,500,000 | $140,175,000 |
All Filings in ACET
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,370,600 | 274,375 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $1,868,493 | 274,375 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $2,310,237 | 274,375 | Shares | Sole | 2026-02-17 | |
| 2021-06-30 | $5,021,520 | 488,000 | Shares | Sole | 2021-08-16 | |
| 2021-03-31 | $6,383,040 | 488,000 | Shares | Sole | 2021-05-17 | |
| No filing history on record for this holder in this stock. | ||||||